当前位置:首页 - 行情中心 - 中国医药(600056) - 财务分析 - 现金流量表

中国医药

(600056)

  

流通市值:152.68亿  总市值:152.73亿
流通股本:14.95亿   总股本:14.96亿

现金流量表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金7,251,831,214.3635,320,534,540.5525,292,280,947.7116,871,965,128.09
收到的税费返还37,038,898.21127,069,084.37121,636,749.0381,610,277.68
收到其他与经营活动有关的现金149,730,342.85796,381,084.761,169,260,231.02629,601,902.98
经营活动现金流入的平衡项目0000
经营活动现金流入小计7,438,600,455.4236,243,984,709.6826,583,177,927.7617,583,177,308.75
购买商品、接受劳务支付的现金7,782,333,031.8831,283,451,498.623,458,767,242.8315,803,262,623.89
支付给职工以及为职工支付的现金427,410,160.711,517,162,123.981,154,183,509.07828,489,874.43
支付的各项税费256,686,197.4936,908,642.46852,772,560.64598,742,317.53
支付其他与经营活动有关的现金453,747,307.851,501,031,895.021,437,881,227.611,038,820,216.43
经营活动现金流出的平衡项目0000
经营活动现金流出小计8,920,176,697.8435,238,554,160.0626,903,604,540.1518,269,315,032.28
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额-1,481,576,242.421,005,430,549.62-320,426,612.39-686,137,723.53
二、投资活动产生的现金流量:
取得投资收益收到的现金--1,367,693.93-
处置固定资产、无形资产和其他长期资产收回的现金净额8,187,430.1943,839,414.21143,223.19140,483.19
收到的其他与投资活动有关的现金-3,6003,6003,600
投资活动现金流入的平衡项目0000
投资活动现金流入小计8,187,430.1943,843,014.211,514,517.12144,083.19
购建固定资产、无形资产和其他长期资产支付的现金61,362,248.21358,624,567.29241,151,821.22160,157,179.81
投资支付的现金-41,020,00040,000,00040,000,000
取得子公司及其他营业单位支付的现金4,134,73911,855,061--
投资活动现金流出的平衡项目0000
投资活动现金流出小计65,496,987.21411,499,628.29281,151,821.22200,157,179.81
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-57,309,557.02-367,656,614.08-279,637,304.1-200,013,096.62
三、筹资活动产生的现金流量:
吸收投资收到的现金400,0009,000,0009,000,0009,000,000
其中:子公司吸收少数股东投资收到的现金400,0009,000,0009,000,0009,000,000
取得借款收到的现金1,469,845,625.66,410,721,930.074,128,608,303.023,137,320,287.81
收到其他与筹资活动有关的现金5,681,057.9772,281,229.7570,399,370.369,400,000
筹资活动现金流入平衡项目0000
筹资活动现金流入小计1,475,926,683.576,492,003,159.824,208,007,673.323,215,720,287.81
偿还债务支付的现金1,264,424,3085,470,430,847.293,656,202,882.722,591,649,533.35
分配股利、利润或偿付利息支付的现金33,284,431.87589,214,420.16530,660,484.99304,469,268.33
其中:子公司支付给少数股东的股利、利润-78,304,855.4865,979,591.3849,301,056.38
支付其他与筹资活动有关的现金131,518,487.8690,591,802.18394,646,196.9898,129,842.29
筹资活动现金流出平衡项目0000
筹资活动现金流出小计1,429,227,227.676,750,237,069.634,581,509,564.692,994,248,643.97
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额46,699,455.9-258,233,909.81-373,501,891.37221,471,643.84
四、汇率变动对现金及现金等价物的影响-842,648.331,779,865.311,887,281.63321,865.34
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-1,493,028,991.87381,319,891.04-971,678,526.23-664,357,310.97
加:期初现金及现金等价物余额3,711,578,829.813,330,258,938.773,330,258,938.773,330,258,938.77
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额2,218,549,837.943,711,578,829.812,358,580,412.542,665,901,627.8
补充资料:
净利润-686,623,882.02-449,756,770.46
资产减值准备-175,325,505.38--1,216,930.7
固定资产和投资性房地产折旧-244,449,774.72-121,465,393.78
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-244,449,774.72-121,465,393.78
无形资产摊销-80,475,955.69-38,624,934.5
长期待摊费用摊销-64,623,194.97-33,263,439.17
处置固定资产、无形资产和其他长期资产的损失--1,653,400.91-102,314.12
固定资产报废损失--1,944,335.44-704,247.05
公允价值变动损失--127,466,901.01-1,108,515.03
财务费用-206,833,463.14-123,441,150.86
投资损失--18,690,363.11--101,264,266.25
递延所得税-2,641,680.61--4,705,275.33
其中:递延所得税资产减少--29,910,011.24--7,209,858.5
递延所得税负债增加-32,551,691.85-2,504,583.17
存货的减少-452,705,276.79-365,937,913.1
经营性应收项目的减少-1,882,963,521.95-156,238,910.88
经营性应付项目的增加--2,964,554,965.04--1,996,276,197.87
其他---6,239,042.2
不涉及现金收支的投资和筹资活动金额其他项目-89,281,494.46--
现金的期末余额-3,711,578,829.81-2,665,901,627.8
减:现金的期初余额-3,330,258,938.77-3,330,258,938.77
公告日期2025-04-302025-04-262024-10-262024-08-21
审计意见(境内)标准无保留意见
TOP↑